Long-term effects of inhaled budesonide on screening-detected lung nodules

Giulia Veronesi, M. Lazzeroni, E. Szabo, P. H. Brown, A. Decensi, A. Guerrieri-Gonzaga, M. Bellomi, D. Radice, M. C. Grimaldi, L. Spaggiari, B. Bonanni

Research output: Contribution to journalArticle

Abstract

Background: A previously carried out randomized phase IIb, placebo-controlled trial of 1 year of inhaled budesonide, which was nested in a lung cancer screening study, showed that non-solid and partially solid lung nodules detected by low-dose computed tomography (LDCT), and not immediately suspicious for lung cancer, tended to regress. Because some of these nodules may be slow-growing adenocarcinoma precursors, we evaluated long-term outcomes (after stopping the 1-year intervention) by annual LDCT. Patients and methods: We analyzed the evolution of target and non-target trial nodules detected by LDCT in the budesonide and placebo arms up to 5 years after randomization. The numbers and characteristics of lung cancers diagnosed during follow-up were also analyzed. Results: The mean maximum diameter of non-solid nodules reduced significantly (from 5.03 mm at baseline to 2.61 mm after 5 years) in the budesonide arm; there was no significant size change in the placebo arm. The mean diameter of partially solid lesions also decreased significantly, but only by 0.69 mm. The size of solid nodules did not change. Neither the number of new lesions nor the number of lung cancers differed in the two arms. Conclusions: Inhaled budesonide given for 1 year significantly decreased the size of non-solid nodules detected by screening LDCT after 5 years. This is of potential importance since some of these nodules may progress slowly to adenocarcinoma. However, further studies are required to assess clinical implications.

Original languageEnglish
Article numbermdv064
Pages (from-to)1025-1030
Number of pages6
JournalAnnals of Oncology
Volume26
Issue number5
DOIs
Publication statusPublished - May 1 2015

Fingerprint

Budesonide
Lung Neoplasms
Tomography
Lung
Placebos
Adenocarcinoma
Random Allocation
Early Detection of Cancer

Keywords

  • Budesonide
  • Chemoprevention
  • Low-dose computed tomography
  • Lung cancer
  • Screening

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Long-term effects of inhaled budesonide on screening-detected lung nodules. / Veronesi, Giulia; Lazzeroni, M.; Szabo, E.; Brown, P. H.; Decensi, A.; Guerrieri-Gonzaga, A.; Bellomi, M.; Radice, D.; Grimaldi, M. C.; Spaggiari, L.; Bonanni, B.

In: Annals of Oncology, Vol. 26, No. 5, mdv064, 01.05.2015, p. 1025-1030.

Research output: Contribution to journalArticle

@article{30571424417843e2a57ba080cd15898d,
title = "Long-term effects of inhaled budesonide on screening-detected lung nodules",
abstract = "Background: A previously carried out randomized phase IIb, placebo-controlled trial of 1 year of inhaled budesonide, which was nested in a lung cancer screening study, showed that non-solid and partially solid lung nodules detected by low-dose computed tomography (LDCT), and not immediately suspicious for lung cancer, tended to regress. Because some of these nodules may be slow-growing adenocarcinoma precursors, we evaluated long-term outcomes (after stopping the 1-year intervention) by annual LDCT. Patients and methods: We analyzed the evolution of target and non-target trial nodules detected by LDCT in the budesonide and placebo arms up to 5 years after randomization. The numbers and characteristics of lung cancers diagnosed during follow-up were also analyzed. Results: The mean maximum diameter of non-solid nodules reduced significantly (from 5.03 mm at baseline to 2.61 mm after 5 years) in the budesonide arm; there was no significant size change in the placebo arm. The mean diameter of partially solid lesions also decreased significantly, but only by 0.69 mm. The size of solid nodules did not change. Neither the number of new lesions nor the number of lung cancers differed in the two arms. Conclusions: Inhaled budesonide given for 1 year significantly decreased the size of non-solid nodules detected by screening LDCT after 5 years. This is of potential importance since some of these nodules may progress slowly to adenocarcinoma. However, further studies are required to assess clinical implications.",
keywords = "Budesonide, Chemoprevention, Low-dose computed tomography, Lung cancer, Screening",
author = "Giulia Veronesi and M. Lazzeroni and E. Szabo and Brown, {P. H.} and A. Decensi and A. Guerrieri-Gonzaga and M. Bellomi and D. Radice and Grimaldi, {M. C.} and L. Spaggiari and B. Bonanni",
year = "2015",
month = "5",
day = "1",
doi = "10.1093/annonc/mdv064",
language = "English",
volume = "26",
pages = "1025--1030",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "5",

}

TY - JOUR

T1 - Long-term effects of inhaled budesonide on screening-detected lung nodules

AU - Veronesi, Giulia

AU - Lazzeroni, M.

AU - Szabo, E.

AU - Brown, P. H.

AU - Decensi, A.

AU - Guerrieri-Gonzaga, A.

AU - Bellomi, M.

AU - Radice, D.

AU - Grimaldi, M. C.

AU - Spaggiari, L.

AU - Bonanni, B.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Background: A previously carried out randomized phase IIb, placebo-controlled trial of 1 year of inhaled budesonide, which was nested in a lung cancer screening study, showed that non-solid and partially solid lung nodules detected by low-dose computed tomography (LDCT), and not immediately suspicious for lung cancer, tended to regress. Because some of these nodules may be slow-growing adenocarcinoma precursors, we evaluated long-term outcomes (after stopping the 1-year intervention) by annual LDCT. Patients and methods: We analyzed the evolution of target and non-target trial nodules detected by LDCT in the budesonide and placebo arms up to 5 years after randomization. The numbers and characteristics of lung cancers diagnosed during follow-up were also analyzed. Results: The mean maximum diameter of non-solid nodules reduced significantly (from 5.03 mm at baseline to 2.61 mm after 5 years) in the budesonide arm; there was no significant size change in the placebo arm. The mean diameter of partially solid lesions also decreased significantly, but only by 0.69 mm. The size of solid nodules did not change. Neither the number of new lesions nor the number of lung cancers differed in the two arms. Conclusions: Inhaled budesonide given for 1 year significantly decreased the size of non-solid nodules detected by screening LDCT after 5 years. This is of potential importance since some of these nodules may progress slowly to adenocarcinoma. However, further studies are required to assess clinical implications.

AB - Background: A previously carried out randomized phase IIb, placebo-controlled trial of 1 year of inhaled budesonide, which was nested in a lung cancer screening study, showed that non-solid and partially solid lung nodules detected by low-dose computed tomography (LDCT), and not immediately suspicious for lung cancer, tended to regress. Because some of these nodules may be slow-growing adenocarcinoma precursors, we evaluated long-term outcomes (after stopping the 1-year intervention) by annual LDCT. Patients and methods: We analyzed the evolution of target and non-target trial nodules detected by LDCT in the budesonide and placebo arms up to 5 years after randomization. The numbers and characteristics of lung cancers diagnosed during follow-up were also analyzed. Results: The mean maximum diameter of non-solid nodules reduced significantly (from 5.03 mm at baseline to 2.61 mm after 5 years) in the budesonide arm; there was no significant size change in the placebo arm. The mean diameter of partially solid lesions also decreased significantly, but only by 0.69 mm. The size of solid nodules did not change. Neither the number of new lesions nor the number of lung cancers differed in the two arms. Conclusions: Inhaled budesonide given for 1 year significantly decreased the size of non-solid nodules detected by screening LDCT after 5 years. This is of potential importance since some of these nodules may progress slowly to adenocarcinoma. However, further studies are required to assess clinical implications.

KW - Budesonide

KW - Chemoprevention

KW - Low-dose computed tomography

KW - Lung cancer

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=84929086937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929086937&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdv064

DO - 10.1093/annonc/mdv064

M3 - Article

AN - SCOPUS:84929086937

VL - 26

SP - 1025

EP - 1030

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 5

M1 - mdv064

ER -